interferon beta-1a SC
Selected indexed studies
- Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation. (Expert Rev Clin Immunol, 2023) [PMID:37694381]
- Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives. (Neurol Ther, 2024) [PMID:38206453]
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. (Cochrane Database Syst Rev, 2023) [PMID:38032059]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation. (2023) pubmed
- [Subcutaneous interferon-beta-1a in the treatment of multiple sclerosis]. (2008) pubmed
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. (2023) pubmed
- Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives. (2024) pubmed
- Interferon Beta-1a versus Combined Interferon Beta-1a and Oligodendrocyte-Specific FGFR1 Deletion in Experimental Autoimmune Encephalomyelitis. (2022) pubmed
- Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study. (2023) pubmed
- Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION. (2021) pubmed
- Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. (2018) pubmed
- Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial. (2020) pubmed
- Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge. (2018) pubmed